Steven M Frisch
Overview
Explore the profile of Steven M Frisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yi W, Dziadowicz S, Mangano R, Wang L, McBee J, Frisch S, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201707
Multiple myeloma is the second most hematological cancer. RUVBL1 and RUVBL2 form a subcomplex of many chromatin remodeling complexes implicated in cancer progression. As an inhibitor specific to the RUVBL1/2...
2.
MacFawn I, Farris J, Pifer P, Margaryan N, Akhter H, Wang L, et al.
Mol Immunol
. 2024 May;
170:156-169.
PMID: 38692097
Type-I and -III interferons play a central role in immune rejection of pathogens and tumors, thus promoting immunogenicity and suppressing tumor recurrence. Double strand RNA is an important ligand that...
3.
Frisch S
Cytokine
. 2022 Apr;
154:155875.
PMID: 35447531
The interleukin-1 proteins are a hub of innate inflammatory signaling that activates diverse aspects of adaptive immunity. Until recently, the IL-1α isoform was relatively incompletely understood compared with IL-1β. This...
4.
Frisch S, MacFawn I
Aging Cell
. 2020 Sep;
19(10):e13234.
PMID: 32918364
This review article addresses the largely unanticipated convergence of two landmark discoveries. The first is the discovery of interferons, critical signaling molecules for all aspects of both innate and adaptive...
5.
MacFawn I, Wilson H, Selth L, Leighton I, Serebriiskii I, Bleackley R, et al.
Mol Immunol
. 2018 Dec;
105:137-149.
PMID: 30508726
Natural Killer (NK) cells suppress tumor initiation and metastasis. Most carcinomas are heterogeneous mixtures of epithelial, mesenchymal and hybrid tumor cells, but the relationships of these phenotypes to NK susceptibility...
6.
Dower C, Wills C, Frisch S, Wang H
Autophagy
. 2018 Jun;
14(7):1110-1128.
PMID: 29863947
Macroautophagy/autophagy is a fundamental cellular degradation mechanism that maintains cell homeostasis, regulates cell signaling, and promotes cell survival. Its role in promoting tumor cell survival in stress conditions is well...
7.
Pifer P, Farris J, Thomas A, Stoilov P, Denvir J, Smith D, et al.
Mol Biol Cell
. 2016 Jun;
27(15):2479-92.
PMID: 27251061
Developmental morphogenesis and tumor progression require a transient or stable breakdown of epithelial junctional complexes to permit programmed migration, invasion, and anoikis resistance, characteristics endowed by the epithelial-mesenchymal transition (EMT)....
8.
Farris J, Pifer P, Zheng L, Gottlieb E, Denvir J, Frisch S
Mol Cancer Res
. 2016 Apr;
14(6):528-38.
PMID: 27084311
Unlabelled: Resistance to anoikis is a prerequisite for tumor metastasis. The epithelial-to-mesenchymal transition (EMT) allows tumor cells to evade anoikis. The wound-healing regulatory transcription factor Grainyhead-like 2 (GRHL2) suppresses/reverses EMT,...
9.
Cieply B, Koontz C, Frisch S
Matrix Biol
. 2015 May;
48:55-65.
PMID: 25937513
The detachment of normal epithelial cells from matrix triggers an apoptotic response known as anoikis, during homeostatic turnover. Metastatic tumor cells evade anoikis, by mechanisms that are only partly characterized....
10.
Frisch S, Schaller M
Cancer Cell
. 2014 May;
25(5):551-2.
PMID: 24823631
In this issue of Cancer Cell, Li and colleagues demonstrate that the hematopoietic transcription factor Aiolos (named after the Wind God of Greek mythology) confers anoikis resistance in lung tumor...